A quinazoline heterocyclic derivative and its preparation method and application

By designing quinazoline heterocyclic derivatives with distorted D-π-A-π-D structure, using phenyl or pyridine as π bridges, the problem of exciton energy emanation in the aggregation state of TADF materials is solved, and fluorescent quantums are improved Yield and luminous efficiency, suitable for efficient organic light emitting devices.

CN116283951BActive Publication Date: 2024-11-19GUANGDONG UNIV OF TECH
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202310296829.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-22
Publication Date
2024-11-19
Estimated Expiration
2043-03-22

AI Technical Summary

Technical Problem

Thermal activated delayed fluorescence (TADF) materials in the aggregation state caused exciton energy to be radiated due to the π-π interaction between molecules, resulting in fluorescence quenching, reducing the luminescence efficiency and fluorescence lifetime. The prior art introduces a matrix with a larger steric hindrance. The group inhibits interaction but has a lower fluorescence quantum yield.

Method used

Design quinazoline heterocyclic derivatives with twisted D-π-A-π-D structure, reduce π-π stacking, limit free rotation of molecules, and improve fluorescence quantum yield by introducing phenyl or pyridine as π bridges. And adjust the frontline molecular orbital distribution in the D-A structure, increase the electron energy level difference, and promote the reverse crossing process.

Benefits of technology

It significantly improves the fluorescence quantum yield, improves the luminous efficiency and luminous intensity, and is suitable for organic light emitting devices, especially in non-doped devices, which show good electroluminescence efficiency.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116283951B_ABST
    Figure CN116283951B_ABST
Patent Text Reader

Abstract

The invention discloses a quinazoline heterocyclic derivative and a preparation method and application thereof, and relates to the field of organic light-emitting materials. The invention uses benzopyrimidine and pyridopyrimidine units containing quinazoline as acceptors, uses phenyl and pyridyl as π bridges, and uses dimethylacridine or phenoxazine as donors to construct an organic small molecule with a D-π-A-π-D structure, reduces π-π stacking through a twisted D-π-A structure, thereby inhibiting fluorescence quenching in an aggregated state, and achieving an increase in fluorescence quantum yield, while controlling the torsion angle between the donor and the acceptor to adjust the frontier molecular orbital distribution, improve the photophysical properties of the material, and is particularly suitable for organic light-emitting material devices.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of organic luminescent materials, and more specifically to a quinazoline heterocyclic derivative and a preparation method and application thereof. Background Art

[0002] Thermally activated delayed fluorescence (TADF) materials can simultaneously utilize 75% of triplet excitons and 25% of singlet excitons, with high luminescence efficiency, and their theoretical maximum internal quantum yield is much higher than that of fluorescent materials with traditional luminescence mechanisms, such as fluorescent materials, phosphorescent materials, and triplet-triplet annihilation (TTA) materials. However, in the aggregated state, since the π-π interaction between TADF material molecules will be significantly enhanced, the energy of most excitons will be dissipated to the external environment in the form of heat energy, resulting in extremely low utilization of excitons and the problem of fluorescence quenching, which reduces the fluorescence lifetime and luminescence intensity of TADF materials and affects their practical applications.

[0003] The existing technology introduces large steric hindrance groups into the molecular design to inhibit the interaction between material molecules, thereby reducing the fluorescence quenching effect and obtaining a thermally activated delayed fluorescent material with aggregation-induced emission characteristics. However, the fluorescence quantum yield of this fluorescent material is low, resulting in low luminous efficiency and luminous intensity, which limits its application. Summary of the invention

[0004] In order to overcome the problem that the existing TADF material with AIE characteristics has low fluorescence quantum yield, resulting in low luminous efficiency, the present invention provides a quinazoline heterocyclic derivative with AIE and TADF characteristics, which improves the fluorescence quantum yield by reducing π-π stacking and restricting the free rotation inside the molecule.

[0005] Another object of the present invention is to provide a method for preparing the above-mentioned quinazoline heterocyclic derivative.

[0006] Another object of the present invention is to provide an application of the above-mentioned quinazoline heterocyclic derivative in an organic light-emitting device.

[0007] The above-mentioned purpose of the present invention is achieved through the following technical solutions:

[0008] A quinazoline heterocyclic derivative having the following general structural formula (I) or (II):

[0009]

[0010] Among them, R and R 1 are independently 10-(pyridin-2-yl)-10H-phenoxazine or 9,9-dimethyl-10-phenyl-9,10-dihydroacridine;

[0011] The hydrogen connected to the nitrogen atom in the 9,9-dimethyl-10-phenyl-9,10-dihydroacridine and 10-(pyridin-2-yl)-10H-phenoxazine is replaced by a phenyl group or a pyridyl group.

[0012] It should be noted that:

[0013] The present invention uses a benzopyrimidine or pyridopyrimidine unit containing quinazoline as an acceptor, uses a phenyl or pyridyl group as a π bridge, and uses 10-(pyridin-2-yl)-10H-phenoxazine or 9,9-dimethyl-10-phenyl-9,10-dihydroacridine as a donor to construct an organic small molecule with a D-π-A-π-D structure, namely a quinazoline heterocyclic derivative. The quinazoline heterocyclic derivative has a distorted conformation, and in an aggregated state, torsion and vibration are suppressed, thereby resulting in a higher radiation transition rate, and has the characteristics of aggregation-induced luminescence and thermally activated delayed fluorescence.

[0014] By constructing a twisted D-π-A structure, π-π stacking can be reduced, thereby improving the fluorescence quantum yield of quinazoline heterocyclic derivatives. In addition, the introduction of phenyl or pyridine as a π bridge in the DA structure can limit the torsion angle between the donor and the acceptor while ensuring a high radiation transition rate and a small singlet and triplet energy level difference, so as to adjust the frontier molecular orbital distribution, avoid fluorescence quenching in the aggregated state, and improve the fluorescence quantum yield.

[0015] In addition, the introduction of the π bridge can increase the distance between the donor and the acceptor, thereby increasing the distance between the HOMO energy level and the LUMO energy level in the frontier molecular orbital, reducing the overlap between the two electronic energy levels, promoting the reverse intersystem crossing (RISC) process, and inhibiting non-radiative transitions, thereby improving the fluorescence quantum yield.

[0016] The structural formula of the 9,9-dimethyl-10-phenyl-9,10-dihydroacridine is The structural formula of 10-(pyridin-2-yl)-10H-phenoxazine is

[0017] Specifically, R is 9,9-dimethyl-10-phenyl-9,10-dihydroacridine, R 1 It is 10-(pyridin-2-yl)-10H-phenoxazine or 9,9-dimethyl-10-phenyl-9,10-dihydroacridine.

[0018] Specifically, the R 1 It is 9,9-dimethyl-10-phenyl-9,10-dihydroacridine.

[0019] Specifically, the structure of the quinazoline-containing heterocyclic compound is

[0020] Preferably, the structure of the quinazoline-containing heterocyclic compound is

[0021] The present invention specifically protects a method for preparing the above-mentioned quinazoline-containing heterocyclic compound, comprising the following steps:

[0022] When the quinazoline heterocyclic derivative has a structure shown in formula (II), the method comprises the following steps:

[0023] S1. The intermediate 1 is mixed with the donor group 1 or the donor group 2 in an organic solvent, and the intermediate 2 is prepared by a suzuki reaction at 95 to 100 ° C under the action of a metal catalyst and an alkaline salt; the structure of the intermediate 2 is:

[0024] S2. The intermediate 2 obtained in S1 is mixed with phosphorus oxychloride and reacted at 60 to 70°C to obtain intermediate 3;

[0025] S3. The intermediate 3 obtained in S2 is mixed with the donor group 1 or the donor group 2 in an organic solvent, and the mixture is fully reacted at 95 to 100° C. under the action of a metal catalyst and an alkaline salt to obtain a compound having a structure represented by formula (II);

[0026] The intermediate 1 is 6-bromoquinoxaline-4-ol; the donor group 1 is 9,9-dimethyl-10-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-9,10-dihydroacridine; the donor group 2 is 10-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-10H-phenoxazine;

[0027] When the quinazoline heterocyclic derivative has a structure shown in formula (I), the method comprises the following steps:

[0028] Mixing 6-bromo-4-chloropyrido[2,3-d]pyrimidine and a donor group in an organic solvent, reacting at 95-100° C. in the presence of a metal catalyst and an alkaline salt to obtain a compound of formula (I);

[0029] The donor group is one or two of the donor group 1 and the donor group 2.

[0030] Specifically, the molar ratio of intermediate 1, donor group 1 or donor group 2, metal catalyst, and alkaline salt in step S1 is 1: (1.05-1.2): (0.05-0.15): (5-7); the reaction time is 8-12 hours.

[0031] Specifically, the reaction time in step S2 is 1.5 to 2.5 hours.

[0032] Specifically, the molar ratio of the intermediate 3, the donor group 1 or the donor group 2, the metal catalyst, and the alkaline salt in step S3 is 1: (1.05-1.2): (0.05-0.15): (5-7); and the reaction time is 8-12 hours.

[0033] Specifically, when the quinazoline heterocyclic derivative has the structure shown in formula (I), the molar ratio of the 6-bromo-4-chloropyrido[2,3-d]pyrimidine, the donor group, the metal catalyst, and the alkaline salt is 1:(2.1-2.3):(0.1-0.2):(5-7).

[0034] Specifically, the structure of the intermediate 1 is: The structure of the intermediate 3 is: The structure of the 9,9-dimethyl-10-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-9,10-dihydroacridine (i.e., donor group 1) is: The structure of the 10-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)-10H-phenoxazine (i.e. donor group 2) is

[0035] The donor group 1 can be purchased conventionally.

[0036] The donor group 2 can be prepared by referring to the following preparation method:

[0037] (1) dissolving phenoxazine, 2-bromo-5-chloropyridine, dibenzylideneacetone dipalladium, tri-tert-butylphosphine tetrafluoroborate, and sodium tert-butoxide in an organic solvent, reacting them fully at 105-110° C., extracting them with saturated saline and ethyl acetate, obtaining an upper organic phase, and performing rotary evaporation; performing column chromatography using a developing solvent of dichloromethane:petroleum ether in a ratio of 1:4 (volume ratio) to obtain 10-(5-chloropyridin-2-yl)-10H-phenoxazine;

[0038]

[0039] The molar ratio of phenoxazine, 2-bromo-5-chloropyridine, dibenzylideneacetone dipalladium, tri-tert-butylphosphine tetrafluoroborate, and strong base is 1:(1-1.1):(0.03-0.05):(0.09-0.15):(2.5-3); the reaction time is 8-12;

[0040] (2) dissolving 10-(5-bromopyridin-2-yl)-10H-phenoxazine, bipyridin-2-yl, catalyst, ligand and alkaline salt in an organic solvent, reacting them at 95-100° C., extracting the crude product with saturated brine and ethyl acetate, obtaining the upper organic phase, rotary evaporating the phase, and passing the phase through a column with a developing solvent of dichloromethane: petroleum ether = 1:2 (volume ratio) to obtain donor group 2;

[0041] The catalyst is dibenzylideneacetone dipalladium, the ligand is 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl, and the alkaline salt is potassium acetate; specifically, the molar ratio of the 10-(5-bromopyridin-2-yl)-10H-phenoxazine, bipyridin-2-yl borate, catalyst, ligand, and alkaline salt is 1:(2-3):(0.03-0.05):(0.09-0.15):(5-7); and the reaction time is 8-12 hours.

[0042] The intermediate 1 can be prepared by referring to the following method:

[0043] 2-amino-5-bromobenzoic acid and formamidine acetate are dissolved in an organic solvent, and the mixture is fully reacted at 130-135° C. 30 ml of saturated saline is added to the reaction solution, the mixture is stirred for 10 minutes, and the intermediate 1 is obtained by suction filtration. The molar ratio of 2-amino-5-bromobenzoic acid to formamidine acetate is 1:(2-3); and the reaction time is 8-12 hours.

[0044] The organic solvent used in the preparation method of the present invention is one of 1,4-dioxane and N,N-dimethylformamide.

[0045] The metal catalyst in the preparation method of the present invention is tetrakistriphenylphosphine palladium, and the alkaline salt is potassium carbonate.

[0046] The present invention particularly protects the use of the above quinazoline heterocyclic derivative in an organic light-emitting material device.

[0047] The quinazoline heterocyclic derivative of the present invention has less π-π stacking, limited free rotation between molecules, and has high fluorescence quantum yield, high luminous efficiency and high luminous intensity even in the aggregated state. In addition, traditional luminescent materials are usually made into doped films during application, and their doping concentration is often difficult to control and affects the luminous efficiency. The quinazoline heterocyclic derivative of the present invention can not only emit strong fluorescence in solid-state films, but also obtain good electroluminescent efficiency in non-doped devices, and is particularly suitable for organic light-emitting material devices.

[0048] Compared with the prior art, the present invention has the following beneficial effects:

[0049] The invention discloses a quinazoline heterocyclic derivative. By constructing a twisted D-π-A structure, π-π stacking is reduced and the solid-state fluorescence quantum yield is improved. At the same time, phenyl or pyridine is introduced into the DA structure as a π bridge to ensure a high radiation transition rate and a small singlet and triplet energy level difference. At the same time, the torsion angle between the donor and the acceptor is controlled, the frontier molecular orbital distribution is adjusted, and the fluorescence quantum yield is improved to obtain ideal photophysical properties.

[0050] The solid-state fluorescence quantum yield of the quinazoline heterocyclic derivative of the invention is above 40%, and reaches 66% at the highest. The high fluorescence quantum yield is beneficial to improving the device efficiency of the organic electroluminescent material. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1 A1 prepared in Example 1 1 HMNR diagram.

[0052] Figure 2 A2 prepared in Example 2 1 HMNR diagram.

[0053] Figure 3 This is the absorption diagram of the compounds prepared in Examples 1 and 2 in toluene solution.

[0054] Figure 4 The emission patterns of the compounds prepared in Examples 1 and 2 in toluene solution.

[0055] Figure 5 The emission patterns of the compounds prepared in Examples 1 and 2 in thin films.

[0056] Figure 6 This is the emission pattern of the compound prepared in Example 1 in tetrahydrofuran aqueous solution.

[0057] Figure 7 This is the emission pattern of the compound prepared in Example 2 in tetrahydrofuran aqueous solution. DETAILED DESCRIPTION

[0058] In a specific embodiment, the preparation method of the 10-(5-bromopyridin-2-yl)-10H-phenoxazine is:

[0059] 2-Bromo-5-chloropyridine (230 mg, 1.2 mmol), phenoxazine (183 mg, 1 mmol), dibenzylideneacetone dipalladium (15 mg, 0.026 mmol), sodium tert-butoxide (290 mg, 3 mmol), tri-tert-butylphosphine tetrafluoroborate (15.1 mg, 0.052 mmol) were put into a 50 ml two-necked flask, 6 ml of toluene was injected under a nitrogen environment, and the mixture was reacted under a nitrogen environment at a temperature of 110° C. The reaction reflux time was 12 h; after the reaction, the mixture was extracted with saturated brine and ethyl acetate to obtain the upper organic phase, which was rotary evaporated; the developing solvent was dichloromethane: petroleum ether = 1:4 (volume ratio) for column chromatography to obtain 10-(5-bromopyridin-2-yl)-10H-phenoxazine (yellow solid, yield: 80%).

[0060] The preparation method of the donor group 2 is:

[0061] 10-(5-chloropyridin-2-yl)-10H-phenoxazine (250 mg, 0.85 mmol), bipyridinyl borate (431 mg, 1.7 mmol), dibenzylideneacetone dipalladium (28 mg, 0.03 mmol), potassium acetate (250 mg, 2.55 mmol), 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (43 mg, 0.09 mmol) were put into a 50 ml two-necked flask, 1,4-dioxane 6 ml was injected under nitrogen environment, and the mixture was reacted under nitrogen environment at a temperature of 80°C, and the reaction reflux time was 12 h; after the reaction, the mixture was extracted with saturated brine and ethyl acetate to obtain the upper organic phase, which was rotary evaporated and passed through a column with a developing solvent of dichloromethane: petroleum ether = 1:2 (volume ratio) to obtain donor group 2 (yellow-green solid, yield: 82%).

[0062]

[0063] The preparation method of the intermediate 1 is:

[0064] 2-Amino-5-bromobenzoic acid (900 mg) and formamidine acetate (1100 mg) were placed in a 50 ml two-necked flask, 20 ml of DMF was injected into the flask, and the mixture was reacted at 130° C. for 12 h. After the reaction, the temperature was cooled to room temperature, 30 ml of saturated brine was added, the mixture was stirred for 10 min, and intermediate 1 (white solid, yield: 95%) was obtained by suction filtration.

[0065]

[0066] The donor group 1 (9,9-dimethyl-10-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-9,10-dihydroacridine) was purchased from Shanghai Bid Pharmaceutical Technology Co., Ltd.

[0067] The present invention is further described below in conjunction with specific embodiments, but the embodiments do not limit the present invention in any form. Unless otherwise specified, the raw materials and reagents used in the embodiments of the present invention are conventionally purchased raw materials and reagents.

[0068] Example 1

[0069] A quinazoline heterocyclic derivative, the structure of which is:

[0070] The above quinazoline heterocyclic derivative A1 can be prepared by referring to the following preparation method:

[0071] S1. The intermediate 1 (180 mg), donor group 1 (Bidder, 363 mg), tetrakistriphenylphosphine palladium (100 mg), and potassium carbonate (664 mg) were placed in a 50 ml two-necked flask, and 16 ml of 1,4-dioxane and 4 ml of deionized water were injected under a nitrogen environment, and the mixture was reacted under a nitrogen environment at a temperature of 100° C. The reaction reflux time was 12 h; after the reaction, the mixture was extracted with saturated brine and ethyl acetate to obtain the upper organic phase, which was rotary evaporated; the mixture was filtered through a column with a developing solvent of ethyl acetate: petroleum ether = 1:2 (volume ratio) to obtain the intermediate 2 (yellow solid, yield: 45%);

[0072]

[0073] S2. Put intermediate 2 (150 mg) and phosphorus oxychloride (2 ml) into a 50 ml two-necked flask, inject 5 ml of toluene under nitrogen environment, slowly add 1 ml of triethylamine, and react under nitrogen environment at 70°C, and the reaction reflux time is 2 hours. After the reaction, quench with 20 ml of saturated sodium bicarbonate solution, then extract with dichloromethane, obtain the lower organic phase, and perform rotary evaporation at 50°C to obtain intermediate 3 (yellow-green solid, yield: 35%), and immediately proceed to the next step of reaction;

[0074]

[0075] S3. Place intermediate 3 (61.1 mg), donor group 2 (58 mg), tetrakistriphenylphosphine palladium (21 mg), and potassium carbonate (133 mg) in a 50 ml two-necked flask, inject 6 ml of 1,4-dioxane and 1.5 ml of deionized water under a nitrogen environment, and react under a nitrogen environment at a temperature of 100°C. The reaction reflux time is 12 hours. After the reaction, extract with saturated brine and ethyl acetate to obtain the upper organic phase, which is rotary evaporated. Use a developing solvent of ethyl acetate: petroleum ether = 1:3 (volume ratio) for column chromatography, and finally obtain quinazoline heterocyclic derivative A1 (bright orange solid, yield: 68%).

[0076]

[0077] Example 2

[0078] A quinazoline heterocyclic derivative, the structure of which is:

[0079] The above quinazoline heterocyclic derivative A2 can be prepared by referring to the following preparation method:

[0080] 6-Bromo-4-chloropyrido[2,3-d]pyrimidine (48.8 mg), donor group 1 (Bild, 181 mg), tetrakistriphenylphosphine palladium (24 mg), potassium carbonate (690 mg) were placed in a 50 ml two-necked flask, 1,4-dioxane 10 ml and deionized water 2.5 ml were injected under nitrogen environment, and the mixture was reacted under nitrogen environment at 100 ° C, and the reaction reflux time was 12 h. After the reaction, the mixture was extracted with saturated brine and ethyl acetate to obtain the upper organic phase, which was then rotary evaporated. The column was passed with a developing solvent of ethyl acetate: petroleum ether = 1:2 (volume ratio), and finally the quinazoline heterocyclic derivative A2 (yellow-orange solid, yield: 71%) was obtained.

[0081]

[0082] Example 3

[0083] A quinazoline heterocyclic derivative, the structure of which is:

[0084] The above-mentioned quinazoline heterocyclic derivative A3 can refer to Example 2, except that the donor group 1 is replaced by the donor group 2.

[0085] Results

[0086] Fluorescence quantum yield test: 3 mg of the above A1, A2 or A3 was taken and solid-state fluorescence quantum yield test was performed on a steady-state transient fluorescence phosphorescence spectrometer (FLS980). The measurement showed that both molecules had high fluorescence quantum yields; the results are shown in Table 1.

[0087] Table 1. Fluorescence quantum yields of quinazoline heterocyclic derivatives of Examples 1 and 2

[0088] Fluorescence quantum yield Example 1 45% Example 2 66%

[0089] As can be seen from Table 1, both A1 and A2 have good solid-state fluorescence quantum yields, can also efficiently emit fluorescence in the aggregated state, and have great potential in the application of high-efficiency organic electroluminescent devices. Among them, the fluorescence quantum yield of the quinazoline heterocyclic derivative A3 in Example 3 is between A1 and A2.

[0090] Figure 1 The hydrogen spectrum was tested on a Bruker 400MHz superconducting NMR instrument. The solvent was deuterated chloroform. Figure 1 It can be seen that its characteristic wave number (ppm) is 1H NMR (400MHz, Chloroform-d) δ9.41 (s, 1H), 8.99 (d, J = 2.1Hz, 1H), 8.44 (s, 1H), 8.32 (s, 2H), 8.23 ​​(dd, J = 8.8, 2.2Hz, 1H), 7.97-7.85 (m, 2H), 7.71-7.34 (m, 7H), 7.12-6.90 (m, 10H), 6.35 (dd, J = 8.0, 1.5Hz, 2H), 1.71 (s, 6H). The peaks can correspond to the hydrogen atoms of the A1 molecule one by one, and the number is reasonable, indicating that the quinazoline-containing heterocyclic compound A1 is synthesized and has a single structure.

[0091] Figure 2 The A2 Bruker 400MHz superconducting NMR instrument was used to test the hydrogen spectrum. The solvent was deuterated chloroform. Figure 2 It can be seen that its characteristic wavenumber (ppm) is 1H NMR (400MHz, Chloroform-d) δ9.71 (d, J = 17.8 Hz, 2H), 8.88 (s, 1H), 8.18 (d, J = 7.8 Hz, 2H), 7.97 (d, J = 7.8 Hz, 2H), 7.68 (d, J = 7.5 Hz, 2H), 7.56 (d, J = 7.5 Hz, 2H), 7.49 (ddd, J =7.4,5.6,1.8Hz,4H),7.11~6.86(m,8H),6.48(dt,J=8.0,1.6Hz,2H),6.34(dd,J=7.9,1.6Hz,2H),1.71(s,12H). The peaks can correspond one-to-one with the hydrogen atoms of the A2 molecule, and the quantity is reasonable, indicating that the quinazoline-containing heterocyclic compound A2 is synthesized with a single structure.

[0092] Figure 3This is the normalized absorption spectrum of molecules A1 and A2 in solution measured by Shimadzu UV-2700 ultraviolet-visible spectrophotometer. There is an absorption band at 350-400nm, which is caused by the electron transition between the donor and the acceptor in the molecule.

[0093] Figure 4 The fluorescence emission spectra of the molecules A1 and A2 were tested at an excitation wavelength of 400 nm. Figure 4 As shown, the emission wavelengths of A1 and A2 molecules in toluene solution are 625 nm and 576 nm, respectively, showing orange-red and yellow light emission in toluene solution, respectively.

[0094] Figure 5 The fluorescence emission spectra of the molecules A1 and A2 in the thin film state are tested at an excitation wavelength of 380 nm. Figure 4 As shown, the emission wavelengths of A1 and A2 molecules in the film are 565nm and 586nm respectively. Compared with the solution, the A1 molecule has a blue shift and the A2 molecule has a slight red shift.

[0095] Figure 6 To test the fluorescence emission spectrum of the obtained molecule A1 in tetrahydrofuran solutions with different water contents at an excitation wavelength of 380nm. Taking advantage of the fact that A1 is insoluble in water but soluble in THF, A1 is first dissolved in THF, and then the water content of the THF solution is adjusted by adding water to the THF solution, thereby changing the aggregation degree of A1 in the THF solution. Finally, the fluorescence intensity of several samples with different water contents is detected, and the relationship between the fluorescence intensity and the water content is found. By observing Figure 6 From the changing relationship between fluorescence intensity and water content, we can see that as the water content in A1 solution increases, its fluorescence emission intensity continues to increase. This result shows that the A1 molecule has an AIE effect.

[0096] Figure 7 The fluorescence emission spectrum of the obtained molecule A2 in tetrahydrofuran solutions with different water contents was tested at an excitation wavelength of 340 nm. The specific testing process is the same as that of the molecule A1. Figure 7 It can be seen that as the water content in the A1 solution increases, its fluorescence emission intensity continues to increase, which shows that the A1 molecule has an AIE effect.

[0097] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the embodiments of the present invention. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the embodiments here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A quinazoline heterocyclic derivative, characterized in that The structure of the quinazoline-containing heterocyclic compound is 2. A method for preparing the quinazoline heterocyclic derivative according to claim 1, characterized in that: The steps include: Mixing 6-bromo-4-chloropyrido[2,3-d]pyrimidine and donor group 1 in an organic solvent, reacting at 95-100° C. under the action of a metal catalyst and an alkaline salt to obtain the quinazoline heterocyclic derivative; The donor group 1 is 9,9-dimethyl-10-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-9,10-dihydroacridine.

3. The preparation method according to claim 2, characterized in that: The molar ratio of the 6-bromo-4-chloropyrido[2,3-d]pyrimidine, the donor group 1, the metal catalyst and the alkaline salt is 1:(2.1-2.3):(0.1-0.2):(5-7).

4. Use of the quinazoline heterocyclic derivative according to claim 1 in an organic light-emitting material device.

Citation Information

Patent Citations

  • Surface active ionic liquid bactericide and application thereof in sterilization of oilfield injection water

    CN102415387A

  • Bipolar compound containing pyridopyrazine unit and preparation method and application of compound

    CN106008501A

  • Organic electroluminescence material and organic photoelectric device

    CN106831743A

  • Quinazoline-containing heterocyclic compound and application of quinazoline-containing heterocyclic compound to organic photoelectric devices

    CN109293583A

  • Small-molecule luminescent materials based on 1,3-benzodiazine (quinazoline) and production method and application of small-molecule luminescent materials based on 1,3-benzodiazine (quinazoline)

    CN110724128A